Justin Schreiber Sells 25,000 Shares of LifeMD, Inc. (NASDAQ:LFMD) Stock

LifeMD, Inc. (NASDAQ:LFMD) CEO Justin Schreiber sold 25,000 shares of the business’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $5.19, for a total value of $129,750.00. Following the transaction, the chief executive officer now owns 2,703,715 shares of the company’s stock, valued at approximately $14,032,280.85. The trade was a 0.92 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Justin Schreiber also recently made the following trade(s):

• On Monday, December 2nd, Justin Schreiber sold 25,000 shares of LifeMD stock. The stock was sold at an average price of $6.52, for a total value of $163,000.00.

LifeMD Stock Up 0.5 %

LifeMD stock traded up $0.03 during mid-day trading on Monday, reaching $5.78. 799,608 shares of the company were exchanged, compared to its average volume of 769,636. LifeMD, Inc. has a 12-month low of $3.99 and a 12-month high of $12.88. The business has a fifty day moving average of $5.50 and a 200 day moving average of $5.58. The firm has a market cap of $250.34 million, a P/E ratio of -9.03 and a beta of 1.49. The company has a debt-to-equity ratio of 10.83, a quick ratio of 0.78 and a current ratio of 0.83.

Institutional Investors Weigh In On LifeMD

A number of institutional investors have recently added to or reduced their stakes in LFMD. ClariVest Asset Management LLC boosted its holdings in shares of LifeMD by 2.9% in the 2nd quarter. ClariVest Asset Management LLC now owns 91,967 shares of the company’s stock valued at $631,000 after buying an additional 2,600 shares in the last quarter. Quest Partners LLC purchased a new stake in LifeMD during the second quarter valued at approximately $31,000. Deerfield Management Company L.P. Series C lifted its position in LifeMD by 25.6% during the second quarter. Deerfield Management Company L.P. Series C now owns 40,289 shares of the company’s stock valued at $276,000 after acquiring an additional 8,204 shares during the last quarter. nVerses Capital LLC acquired a new stake in LifeMD in the third quarter valued at approximately $46,000. Finally, Intech Investment Management LLC purchased a new position in LifeMD in the third quarter worth $54,000. Institutional investors own 35.52% of the company’s stock.

Analysts Set New Price Targets

LFMD has been the subject of a number of research analyst reports. HC Wainwright reiterated a “buy” rating and set a $12.00 price objective on shares of LifeMD in a report on Monday, November 11th. Lake Street Capital initiated coverage on shares of LifeMD in a research note on Tuesday, December 10th. They set a “buy” rating and a $12.00 price target for the company. Mizuho initiated coverage on LifeMD in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $7.00 price objective on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $15.00 target price on shares of LifeMD in a research report on Friday, September 20th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $11.57.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.